Nomura Holdings
IOVA icon

Nomura Holdings’s Iovance Biotherapeutics IOVA Stock Holding History

Nomura Holdings’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-17,500
Closed -$130K – 2047
2024
Q4 		$130K Buy
+17,500
New +$162K ﹤0.01% 2090
2024
Q2 		– Sell
-34,000
Closed -$504K – 1879
2024
Q1 		$504K Sell
34,000
-66,000
-66% -$768K ﹤0.01% 1256
2023
Q4 		$813K Sell
100,000
-42,000
-30% -$220K ﹤0.01% 1235
2023
Q3 		$646K Buy
+142,000
New +$927K ﹤0.01% 1079

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Nomura Holdings's IOVA Position: Q1 2025 in Review

Nomura Holdings sold out of Iovance Biotherapeutics (IOVA) in Q1 2025, closing a stake of 26,500 shares — an estimated $196K sold.

Nomura Holdings first reported a position in IOVA in Q4 2018 and held it in 15 quarters. The position peaked at $13.2M in Q2 2022. 301 funds tracked by Wall St. Rank hold IOVA as of Q1 2025.

  • Nomura Holdings reported no remaining Iovance Biotherapeutics position as of Q1 2025 after selling out during the quarter.
  • Nomura Holdings sold 26,500 Iovance Biotherapeutics shares in Q1 2025, an estimated $196K.
  • Nomura Holdings first reported a position in Iovance Biotherapeutics in Q4 2018 and held it in 15 quarters.
  • Nomura Holdings's Iovance Biotherapeutics position peaked at $13.2M in Q2 2022.
  • 301 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2025.

Based on Nomura Holdings's 13F filing for Q1 2025, filed 15 May 2025.